Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST.

iScience

The Lautenberg Center for Immunology and Cancer Research, the Hebrew University, Medical School Hadassah Ein Karem, Israel, Jerusalem.

Published: August 2023

Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) secretion-enhancing lncRNA nettoie Salmonella pas Theiler's (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFN release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFN secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth . Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710PMC
http://dx.doi.org/10.1016/j.isci.2023.107284DOI Listing

Publication Analysis

Top Keywords

yts cells
16
seyts cells
12
cells
9
selectively enhanced
8
yts
5
eradication cd48-positive
4
cd48-positive tumors
4
tumors selectively
4
enhanced yts
4
cells harnessing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!